Evidence map›Paper›PMID 40261025›Full record

ArticlemSphere2025

Characterization of a novel

Bianca de Oliveira, Wanessa M Goes, Frederico C Nascimento, Juliana B T Carnielli, Eden R Ferreira, Alex Fiorini de Carvalho, Pablo Victor Mendes Dos Reis, Milton Pereira, Tiago Queiroga Nery Ricotta, Liliane Martins Dos Santos and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bianca de OliveiraCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0001-6572-4147
Wanessa M GoesCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-1323-432X
Frederico C NascimentoFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Juliana B T CarnielliYork Biomedical Research Institute, Department of Biology, University of York, York, United Kingdom.
Eden R FerreiraYork Biomedical Research Institute, Department of Biology, University of York, York, United Kingdom.
Alex Fiorini de CarvalhoCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Pablo Victor Mendes Dos ReisCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Milton PereiraCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Tiago Queiroga Nery RicottaFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Liliane Martins Dos SantosFaculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Renan Pedra de SouzaCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Diego Esteban CargneluttiInstituto de Medicina y Biología Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Cuyo (UNCuyo), Mendoza, Argentina.
Jeremy C MottramYork Biomedical Research Institute, Department of Biology, University of York, York, United Kingdom.ORCID 0000-0001-5574-3766
Santuza R TeixeiraCentro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-2588-2842
Ana Paula Fernandes *Centro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-6208-548X
Ricardo T Gazzinelli *Centro de Tecnologia de Vacinas (CTVacinas), Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0003-2427-7699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human visceral leishmaniasis (HVL) is the second most lethal tropical parasitic disease. Currently, no prophylactic or therapeutic vaccines exist for HVL. Thus, the development of an efficacious vaccine is still needed. We previously performed an immunoproteomics analysis on IMPORTANCE: A previous reverse vaccinology study identified kinetoplast-associated protein-like protein from

Indexed as

Antigens, ProtozoanLeishmaniaLeishmania infantumLeishmaniasis VaccinesLeishmaniasis, VisceralAnimalsAntibodies, ProtozoanFemaleHumansMiceMice, Inbred BALB CProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanLeishmaniasis VaccinesProtozoan Proteinsadjuvantsimmune responseleishmaniasisprotein localizationrecombinant protein productionvaccines

Identifiers

PMID40261025
PMCPMC12108087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.